Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christie, M. R.
Right arrow Articles by Ziegler, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christie, M. R.
Right arrow Articles by Ziegler, A. G.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 6 965-970, Copyright © 1997 by American Diabetes Association


ARTICLES

Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins

MR Christie, U Roll, MA Payton, EC Hatfield and AG Ziegler
Department of Medicine, King's College School of Medicine, London, U.K. m.christie@kcl.ac.uk

OBJECTIVE: To determine whether screening for the presence of multiple antibody markers for IDDM is effective at identifying individuals with high risk for disease development. RESEARCH DESIGN AND METHODS: Antibodies to GAD and the tyrosine phosphatase-like protein 1A-2 were determined in sequential serum samples from 44 first-degree relatives of IDDM patients, identified as possessing islet cell antibody (ICA) and/or insulin autoantibody (IAA), who were followed prospectively for IDDM development, ICA, IAA, and antibodies to GAD and 1A-2 were also determined in 93 cases of new-onset nonfamilial IDDM. RESULTS: The presence of two or more antibodies in addition to ICA or IAA conferred high risk (61%) for development of IDDM within 5 years of entry into the study and identified 89% of those who have developed IDDM on current follow-up. None of the relatives positive for ICA or IAA alone, in the absence of other antibody markers, have developed IDDM. Antibodies to islet antigens could both appear and disappear in follow-up samples obtained after entry into the study. The majority (60%) of young (< 16 years), sporadic cases of IDDM had multiple antibodies to islet antigens, but this proportion was lower in older patients (37%). CONCLUSIONS: A screening strategy based on the analysis of antibodies to multiple islet antigens can predict IDDM at high sensitivity and specificity in families, and such a strategy may also be applicable to identify young individuals in the general population with high disease risk. Since appearance of antibodies to different antigens occurs sequentially rather than simultaneously, accurate assessment of diabetes risk based on the presence of multiple antibodies will require follow-up over a number of years after the first evidence of islet autoimmunity.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
I. Y. Jarvela, J. Juutinen, P. Koskela, A.-L. Hartikainen, P. Kulmala, M. Knip, and J. S. Tapanainen
Gestational Diabetes Identifies Women at Risk for Permanent Type 1 and Type 2 Diabetes in Fertile Age: Predictive role of autoantibodies.
Diabetes Care, March 1, 2006; 29(3): 607 - 612.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
W. E. Winter, N. Harris, and D. Schatz
Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes
Clin. Diabetes, October 1, 2002; 20(4): 183 - 191.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro
IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin
Diabetes Care, July 1, 2002; 25(7): 1192 - 1197.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
J. M. LaGasse, M. S. Brantley, N. J. Leech, R. E. Rowe, S. Monks, J. P. Palmer, G. T. Nepom, D. K. McCulloch, and W. A. Hagopian
Successful Prospective Prediction of Type 1 Diabetes in Schoolchildren Through Multiple Defined Autoantibodies: An 8-year follow-up of the Washington State Diabetes Prediction Study
Diabetes Care, March 1, 2002; 25(3): 505 - 511.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. Savola, E. Laara, P. Vahasalo, P. Kulmala, H. K. Akerblom, and M. Knip
Dynamic Pattern of Disease-Associated Autoantibodies in Siblings of Children With Type 1 Diabetes: A Population-Based Study
Diabetes, November 1, 2001; 50(11): 2625 - 2632.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. Imagawa, T. Hanafusa, J.-i. Miyagawa, Y. Matsuzawa, and The Osaka IDDM Study Group
A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies
N. Engl. J. Med., February 3, 2000; 342(5): 301 - 307.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. Mrena, K. Savola, P. Kulmala, H. K. Åkerblom, M. Knip, and the Childhood Diabetes in Finland Study Group
Staging of Preclinical Type 1 Diabetes in Siblings of Affected Children
Pediatrics, October 1, 1999; 104(4): 925 - 930.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
E. Bonifacio, V. Lampasona, and P. J. Bingley
IA-2 (Islet Cell Antigen 512) Is the Primary Target of Humoral Autoimmunity Against Type 1 Diabetes-Associated Tyrosine Phosphatase Autoantigens
J. Immunol., September 1, 1998; 161(5): 2648 - 2654.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.